Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections

被引：3
|
作者：
Arsuffi, Stefania [1 ,2 ]
Sansone, Emanuele [2 ,3 ]
Foca, Emanuele [1 ,2 ]
Storti, Samuele [1 ,2 ]
Diaferia, Teresa [2 ,3 ]
Bonfanti, Carlo [2 ,4 ]
Terlenghi, Luigina [2 ,4 ]
Caruso, Arnaldo [2 ,4 ]
Sala, Emma [2 ,3 ]
Castelli, Francesco [1 ,2 ]
De Palma, Giuseppe [2 ,3 ]
Quiros-Roldan, Eugenia [1 ,2 ]
机构：
[1] Univ Brescia, Unit Infect & Trop Dis, Brescia, Italy
[2] ASST Spedali Civili Hosp, Brescia, Italy
[3] Univ Brescia, Dept Occupat Hlth & Ind Hyg, Brescia, Italy
[4] Univ Brescia, Microbiol Dept, Brescia, Italy
来源：
ISCIENCE | 2023年 / 26卷 / 01期
关键词：
HEALTH-CARE WORKERS; COVID-19; ANTIBODY;
D O I：
10.1016/j.isci.2023.106716
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
COVID-19 vaccines elicit a strong anti-S antibodies response. We aim to describe antibody titers in peri-vaccination SARS-CoV-2 infections. This is a retrospective longitudinal single-cohort study. Serological tests were performed at the time of the first SARS-CoV-2 vaccine dose (T0) and 60 (T1), 120 (T2), and 240 (T3) days after. The study included 4,682 subjects. Group A had the infection without an anti-S Ig response. Group B and C seroconverted for anti-N Ig between T0 and T1 and be-tween T1 and T2, respectively. Group D was persistently anti-N Ig negative. Group B showed an initial sub-optimal response, reaching the highest titer at T3. Those who received the second dose 120 days after the infection had higher titers compared to those who received it 21 days after the first dose. The immune response depends on the number and the timing of vaccine doses, highlighting the need for a more personalized approach to vaccination.
引用
收藏
页数：12
相关论文
共 50 条
  • [41] Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
    Brinkley-Rubinstein, Lauren
    Peterson, Meghan
    Martin, Rosemarie
    Chan, Philip
    Berk, Justin
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (11): : 1051 - 1052
  • [42] SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in people with multiple sclerosis treated with ocrelizumab (OCR)
    Bar-Or, A.
    Bhargava, P.
    Patti, F.
    Killestein, J.
    Vollmer, T.
    Raposo, C.
    Craveiro, L.
    Jessop, N.
    Pedotti, R.
    Kuenzel, T.
    Lebrun-Frenay, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 512 - 513
  • [43] Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel
    Maltezou, H. C.
    Gamaletsou, M. N.
    Giannouchos, T. V.
    Koukou, D-M.
    Karapanou, A.
    Sourri, F.
    Syrimi, N.
    Lemonakis, N.
    Peskelidou, E.
    Papanastasiou, K.
    Souliotis, K.
    Lourida, A.
    Panagopoulos, P.
    Hatzigeorgiou, D.
    Sipsas, N. V.
    JOURNAL OF HOSPITAL INFECTION, 2023, 132 : 46 - 51
  • [44] Immune implications of SARS-CoV-2 in Nasopharynx
    Ordovas-Montanes, Jose
    Ziegler, Carly
    Williams, Haley
    Abraham, George
    Robinson, Tanya
    Senitko, Michal
    Sloan, Meredith
    Owings, Anna
    Laird, Hannah
    Christian, Taylor
    Parker, Adam
    Pride, Yilianys
    Navia, Andrew
    Miao, Vincent
    Tang, Ying
    Horwitz, Bruce
    Shalek, Alex
    Glover, Sarah
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S92 - S92
  • [45] Editorial: Immune response to SARS-CoV-2 and implications for clinical outcome
    Boelke, Edwin
    van Griensven, Martijn
    Schneider, E. Marion
    Fischer, Johannes C.
    Feldt, Torsten
    Keitel, Verena
    Budach, Wilfried
    Haussmann, Jan
    Jazmati, Danny
    Matuschek, Christiane
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
    Dzinamarira, Tafadzwa
    Tungwarara, Nigel
    Chitungo, Itai
    Chimene, Munashe
    Iradukunda, Patrick Gad
    Mashora, Moreblessing
    Murewanhema, Grant
    Rwibasira, Gallican Nshogoza
    Musuka, Godfrey
    VACCINES, 2022, 10 (02)
  • [47] Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development
    Miyamoto, Sho
    Suzuki, Tadaki
    VACCINE, 2024, 42 (06) : 1401 - 1406
  • [48] The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
    Molaei, Soheila
    Dadkhah, Masoomeh
    Asghariazar, Vahid
    Karami, Chiman
    Safarzadeh, Elham
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
  • [49] Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses
    Buscot, Matthieu
    Cremoni, Marion
    Graca, Daisy
    Brglez, Vesna
    Courjon, Johan
    Allouche, Jonathan
    Teisseyre, Maxime
    Boyer, Laurent
    Barriere, Jerome
    Chamorey, Emmanuel
    Carles, Michel
    Seitz-Polski, Barbara
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections
    Alirezaylavasani, Amin
    Skeie, Linda Gail
    Egner, Ingrid Marie
    Chopra, Adity
    Dahl, Tuva Borresdatter
    Prebensen, Christian
    Vaage, John Torgils
    Halvorsen, Bente
    Lund-Johansen, Fridtjof
    Tonby, Kristian
    Reikvam, Dag Henrik
    Stiksrud, Birgitte
    Holter, Jan Cato
    Dyrhol-Riise, Anne Ma
    Munthe, Ludvig A.
    Kared, Hassen
    NPJ VACCINES, 2024, 9 (01)
12345